Methods for modulating regulatory T cells, regulatory b cells, and immune responses using modulators of the april-taci interaction
AssigneeDana-Farber Cancer Institute, Inc.
InventorsKenneth C. Anderson, Yu-Tzu Tai
Life of this patent
Estimating the term…
Abstract
The present invention is based, in part, on methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction.
Claims20
An in vitro or ex vivo method of selectively decreasing the number and/or inhibitory immune activity of Tregs and/or Bregs comprising contacting the Tregs and/or Bregs with 1) an immune checkpoint therapy comprising an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-PD-L2 antibody, and 2) an antibody that blocks the interaction of TACI receptor protein expressed by the Tregs and/or Bregs with APRIL ligand and selectively decreases the number and/or inhibitory immune activity of the Tregs and/or Bregs, wherein the antibody that blocks the interaction of TACI receptor protein expressed by the Tregs and/or Bregs with APRIL ligand is an anti-APRIL antibody or an anti-TACI antibody.
Dependencies are inferred from the claim text.